Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Nanotherapies For The Treatment Of Ocular Diseases.

S. Reimondez-Troitiño, N. Csaba, M. Alonso, M. de la Fuente
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The topical route is the most frequent and preferred way to deliver drugs to the eye. Unfortunately, the very low ocular drug bioavailability (less than 5%) associated with this modality of administration, makes the efficient treatment of several ocular diseases a significant challenge. In the last decades, it has been shown that specific nanocarriers can interact with the ocular mucosa, thereby increasing the retention time of the associated drug onto the eye, as well as its permeability across the corneal and conjunctival epithelium. In this review, we comparatively analyze the mechanism of action and specific potential of the most studied nano-drug delivery carriers. In addition, we present the success achieved until now using a number of nanotherapies for the treatment of the most prevalent ocular pathologies, such as infections, inflammation, dry eye, glaucoma, and retinopathies.
This paper references
Gene therapy for glaucoma: treating a multifaceted, chronic disease.
T. Borrás (2002)
10.1016/S0378-5173(00)00508-1
Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies.
A. Gupta (2000)
10.1016/j.jconrel.2010.10.007
Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling.
Hany S M Ali (2011)
10.1016/j.ijpharm.2009.06.020
Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery.
N. Li (2009)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
10.1016/j.ejmech.2009.10.017
Designing dendrimers for ocular drug delivery.
G. Spataro (2010)
10.1016/J.JCONREL.2005.11.020
W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention.
R. Alany (2006)
10.1248/CPB.59.272
Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study.
R. C. Nagarwal (2011)
10.3109/02652048609049580
A solid colloidal drug delivery system for the eye: encapsulation of pilocarpin in nanoparticles.
T. Harmia (1986)
10.1016/j.addr.2009.11.026
Chitosan-based nanostructures: a delivery platform for ocular therapeutics.
M. de la Fuente (2010)
10.1016/0014-4835(77)90282-2
A study of the transfer of amino acids across the endothelium of the rabbit cornea.
M. Riley (1977)
10.1111/j.1755-3768.2009.01584.x
Liposomes as an ocular delivery system of fluconazole: in‐vitro studies
F. Habib (2010)
10.1111/jphp.12089
Rapamycin‐loaded poly(ε‐caprolactone)‐poly(ethylene glycol)‐poly(ε‐caprolactone) nanoparticles: preparation, characterization and potential application in corneal transplantation
Zhaoliang Zhang (2014)
10.3109/02713683.2010.508867
In Vivo Evaluation of Novel Nanoparticles Containing Dexamethasone for Ocular Drug Delivery on Rabbit Eye
Farzaneh Rafie (2010)
10.1167/IOVS.02-1142
Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines.
S. Dey (2003)
10.1111/jphp.12075
Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery
Philippe Daull (2014)
10.1039/9781849735292-00173
Nanostructures overcoming the ocular barrier : physiological considerations and mechanistic issues
C. Wilson (2012)
10.1208/aapsj0903044
Preparation and ocular pharmacokinetics of ganciclovir liposomes
Y. Shen (2008)
10.1371/journal.pone.0021967
Genome-Wide Linkage Scan for Primary Open Angle Glaucoma: Influences of Ancestry and Age at Diagnosis
K. Crooks (2011)
10.1208/s12249-011-9643-9
Nanovesicular Formulation of Brimonidine Tartrate for the Management of Glaucoma: In Vitro and In Vivo Evaluation
Sabyasachi Maiti (2011)
10.3109/1061186X.2010.504268
Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery
H. Gupta (2011)
10.1016/S0928-0987(03)00178-7
The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa.
A. M. de Campos (2003)
10.3109/03639040903099751
Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment
M. Mehanna (2010)
Paracellular permeability of corneal and conjunctival epithelia.
A. Huang (1989)
10.1126/SCIENCE.1078192
Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles
R. Savić (2003)
10.1038/mt.2009.181
Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous.
D. Dalkara (2009)
10.1016/j.ijpharm.2012.07.024
Liposomal diclofenac eye drop formulations targeting the retina: formulation stability improvement using surface modification of liposomes.
Takuya Fujisawa (2012)
Liposomes in topical drug delivery.
H. E. Schaeffer (1982)
10.1016/j.ejmech.2008.06.012
PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist.
V. Gajbhiye (2009)
10.1016/j.ijpharm.2011.01.004
Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers.
C. Di Tommaso (2011)
10.1016/j.jconrel.2011.01.010
Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
P. Aksungur (2011)
10.1002/jcp.24398
The cellular mechanisms of dry eye: From pathogenesis to treatment
F. Mantelli (2013)
10.1002/jps.22422
Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery.
H. Abdelkader (2011)
10.1002/mabi.201100005
Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy.
G. K. Zorzi (2011)
10.1021/bm4018879
Dithiol-PEG-PDLLA micelles: preparation and evaluation as potential topical ocular delivery vehicle.
J. Yang (2014)
10.1016/S0168-3659(98)00107-2
Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn.
S. Klang (1999)
10.1016/0378-5173(88)90060-9
Solubilization of tropicamide by poloxamers: physicochemical data and activity data in rabbits and humans
M. Saettone (1988)
10.1016/j.jconrel.2014.03.030
Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery.
V. Pawar (2014)
10.1016/S0168-3659(96)01503-9
Ex-vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea
S. Muchtar (1997)
Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells
Laura Contreras-Ruiz (2011)
10.1167/iovs.07-1077
Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy.
M. de la Fuente (2008)
10.1038/gt.2012.56
A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model
L. Contreras-Ruiz (2013)
10.1016/S0378-5173(99)00265-3
Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery.
M. Nagarsenker (1999)
10.2174/1567201811310050001
Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy.
Kunal Jain (2013)
10.1016/0378-5173(86)90053-0
Enhancement of the myotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate nanoparticles
T. Harmia (1986)
10.1002/smll.201303433
Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes.
Benjamin M. Davis (2014)
10.1016/j.ijpharm.2010.10.008
Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.
Jie Shen (2010)
10.1016/j.ejpb.2012.02.014
Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
C. Di Tommaso (2012)
10.1006/BBRC.1996.0326
Gene transfer to the retina of rat by liposome eye drops.
T. Matsuo (1996)
10.1016/j.ijpharm.2011.03.041
Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect.
J. Shen (2011)
10.1016/0378-5173(85)90007-9
Ocular disposition of poly-hexyl-2-cyano[3-14C]acrylate nanoparticles in the albino rabbit
R. Wood (1985)
10.1016/S0939-6411(98)00098-8
Studies on the effect of pilocarpine incorporation into a submicron emulsion on the stability of the drug and the vehicle.
K. Zurowska-Pryczkowska (1999)
10.2174/1872211308666140130093301
Drug delivery to the back of the eye following topical administration: an update on research and patenting activity.
S. H. S. Boddu (2014)
10.1007/S003960050050
Development of positively charged colloidal drug carriers: Chitosan-coated polyester nanocapsules and submicron-emulsions
P. Calvo (1997)
10.3109/02713689008999587
Lactate-proton cotransport in rabbit corneal epithelium.
J. Bonanno (1990)
10.1208/s12249-010-9388-x
Dual-Drug Delivery System Based on In Situ Gel-Forming Nanosuspension of Forskolin to Enhance Antiglaucoma Efficacy
S. Gupta (2010)
10.2147/IJN.S595
Nanocrystal technology, drug delivery and clinical applications
Jens-Uwe A. H. Junghanns (2008)
10.1111/jphp.12104
Dendrimers for gene delivery – a potential approach for ocular therapy?
Sahil P. Chaplot (2014)
10.1089/jop.2012.0232
Dendrimer nanoparticles for ocular drug delivery.
S. Kambhampati (2013)
10.1517/17425240902762818
Chitosan nanoparticles for drug delivery to the eye
P. Paolicelli (2009)
10.1016/j.ijpharm.2014.03.048
Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo.
A. Tuomela (2014)
10.1016/S0378-5173(02)00080-7
Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin.
R. Cavalli (2002)
10.2174/1874104500802010066
Transcorneal Permeation in a Corneal Device of Non-Steroidal Anti-Inflammatory Drugs in Drug Delivery Systems
R. Valls (2008)
10.1167/IOVS.05-0495
Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.
Amalia Enríquez de Salamanca (2006)
10.2147/IJN.S28307
Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide
John Youshia (2012)
10.3109/02713688209000783
Ocular distribution of liposome-encapsulated epinephrine and inulin in the albino rabbit.
R. Stratford (1982)
10.1016/j.ijpharm.2012.04.063
Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea models.
H. Abdelkader (2012)
10.1016/J.JCONREL.2004.09.015
Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide.
Th F Vandamme (2005)
10.1097/ICU.0b013e32835cfe92
Nanotechnology and glaucoma: little particles for a big disease
D. Pita-Thomas (2013)
10.1016/j.jconrel.2014.03.026
PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications.
Keru Zhang (2014)
10.1021/mp200155t
Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles.
Giovanni Konat Zorzi (2011)
10.1167/iovs.10-5388
Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin.
C. Durairaj (2010)
10.1016/J.IJPHARM.2007.01.019
Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor.
Deepika Aggarwal (2007)
10.1016/J.CARBPOL.2006.01.020
Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface
Xu-bo Yuan (2006)
10.1016/S0378-5173(97)00083-5
Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers
P. Calvo (1997)
10.1001/archophthalmol.2010.172
Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome.
M. Genead (2010)
10.1136/bjo.2005.073817
Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review
S. Sivaprasad (2005)
10.1038/nrg3763
Non-viral vectors for gene-based therapy
H. Yin (2014)
10.1016/j.ijpharm.2012.10.015
Development of O/W nanoemulsions for ophthalmic administration of timolol.
M. Gallarate (2013)
10.1111/jphp.12249
Advances in ophthalmic drug delivery
T. Singh (2014)
10.1016/J.IJPHARM.2005.09.023
Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Ahmed S. Guinedi (2005)
10.1081/PDT-100102035
Influence of Emulsion Droplet Surface Charge on Indomethacin Ocular Tissue Distribution
S. Klang (2000)
10.3109/10837450903479988
Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes
G. Abdelbary (2011)
10.1016/J.IJPHARM.2007.07.045
Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation.
Xubo Yuan (2008)
10.1002/14651858.CD006539.pub4
Neuroprotection for treatment of glaucoma in adults.
D. Sena (2017)
10.1111/j.2042-7158.1991.tb03534.x
Improvement of Ocular Penetration of Amikacin Sulphate by Association to Poly(butylcyanoacrylate) Nanoparticles
C. Losa (1991)
10.1016/j.ophtha.2011.11.003
Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.
Elma E Chang (2012)
10.2165/00003495-199652040-00006
Common Ocular Infections
S. Donahue (2012)
10.1007/s40123-014-0021-z
Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
L. Schopf (2014)
10.3109/02652049109021873
Studies on the transport pathway of PBCA nanoparticles in ocular tissues.
A. Zimmer (1991)
10.1002/APP.35229
Pilocarpine‐loaded poly(DL‐lactic‐co‐glycolic acid) nanoparticles as potential candidates for controlled drug delivery with enhanced ocular pharmacological response
K. Nair (2012)
10.1021/NN301873V
Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration.
H. Yang (2012)
10.1039/b904746h
Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers.
Analette I. Lopez (2009)
10.1016/j.jtos.2014.01.004
Interfacial phenomena and the ocular surface.
B. Yáñez-Soto (2014)
Demonstration of the mucous layer of the tear film by electron microscopy.
B. Nichols (1985)
10.1211/0022357044896
Development of a topical niosomal preparation of acetazolamide: preparation and evaluation
Deepika Aggarwal (2004)
10.1016/j.ijpharm.2010.10.013
Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system.
Q. Luo (2011)
10.1021/mp900279c
Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy.
H. K. Ibrahim (2010)
10.1111/j.2042-7158.1996.tb03911.x
Improved Ocular Bioavailability of Indomethacin by Novel Ocular Drug Carriers
P. Calvo (1996)
10.1016/J.IJPHARM.2004.10.026
Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system.
Deepika Aggarwal (2005)
10.1016/j.nano.2011.08.018
Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs.
C. A. Holden (2012)
10.1016/0168-3659(85)90057-4
Ocular therapy with nanoparticulate systems for controlled drug delivery
R. Gurny (1985)
10.1002/mabi.201000388
Advances in mucoadhesion and mucoadhesive polymers.
V. Khutoryanskiy (2011)
10.1016/J.BIOMATERIALS.2006.11.028
Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP).
Y. Diebold (2007)
10.1111/jphp.12132
Topical delivery of ocular therapeutics: carrier systems and physical methods
J. G. Souza (2014)
10.1007/s12272-001-1266-6
Chitosan based nanocarriers for indomethacin ocular delivery
A. Badawi (2008)
10.1016/j.exer.2008.08.011
Glaucoma-associated myocilin: a better understanding but much more to learn.
Z. Resch (2009)
PREPARATION AND IN-VITRO EVALUATION OF DICLOFENAC SODIUM NIOSOMAL FORMULATIONS
Marwa Helmy Abedullahh (2013)
10.1111/j.1755-3768.1993.tb07146.x
Ocular fatigue is the major symptom of dry eye
I. Toda (1993)
10.1016/S0002-9394(00)00538-9
The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration
F. Ederer (2000)
10.2174/1389200043335342
Role of metabolism in ocular drug delivery.
Sridhar Duvvuri (2004)
10.1016/S0378-5173(99)00106-4
Miotic effect and irritation potential of pilocarpine prodrug incorporated into a submicron emulsion vehicle.
M. Sznitowska (1999)
10.1023/A:1013671819604
Cyclosporine A Formulation Affects Its Ocular Distribution in Rabbits
M. Kuwano (2004)
10.1016/j.nano.2009.10.004
Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.
H. Gupta (2010)
10.17925/EOR.2012.06.03.173
Current Use of Non-steroidal Anti-inflammatory Drugs in the Treatment of Ocular Inflammation Related to Cataract Surgery
E. Donnenfeld (2012)
10.1208/pt0801001
Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies
Rania M. Hathout (2008)
10.2147/IJN.S65601
Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion
P. R. Karn (2014)
10.2147/OPTH.S6225
The effects of lubricant eye drops on visual function as measured by the Inter-blink interval Visual Acuity Decay test
G. Torkildsen (2009)
10.1016/0039-6257(93)90141-S
Minimizing systemic absorption of topically administered ophthalmic drugs.
A. Urtti (1993)
10.1097/ICO.0b013e3181bd9eee
Ocular Tolerance to a Topical Formulation of Hyaluronic Acid and Chitosan-Based Nanoparticles
L. Contreras-Ruiz (2010)
10.1016/j.ijpharm.2014.02.038
A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases.
P. S. Apaolaza (2014)
10.1016/J.IJPHARM.2003.09.016
Vesicular systems in ocular drug delivery: an overview.
I. P. Kaur (2004)
10.1016/0378-5173(94)90179-1
Study of the mechanism of interaction of poly(ϵ-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy
P. Calvo (1994)
10.1016/j.ijpharm.2012.08.016
Cyclosporin nanosphere formulation for ophthalmic administration.
Wahid Khan (2012)
10.1016/S0168-3659(99)00192-3
Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption.
S. Law (2000)
10.1016/S0378-5173(01)00760-8
Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A.
A. M. de Campos (2001)
10.1002/jps.22137
A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation.
Ivan Pepić (2010)
10.1016/j.addr.2008.09.002
Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery.
Jim Jiao (2008)
10.1023/B:PHAM.0000026432.75781.cb
Chitosan Nanoparticles as New Ocular Drug Delivery Systems: in Vitro Stability, in Vivo Fate, and Cellular Toxicity
A. M. de Campos (2004)
10.1007/s11095-006-9122-2
Transport of Poly(Amidoamine) Dendrimers across Caco-2 Cell Monolayers: Influence of Size, Charge and Fluorescent Labeling
Kelly M. Kitchens (2006)
10.1016/0378-5173(83)90075-3
Effects of topically applied liposomes on disposition of epinephrine and inulin in the albino rabbit eye
R. Stratford (1983)
10.1016/j.ijpharm.2009.05.028
Polyhydroxyethylaspartamide-based micelles for ocular drug delivery.
C. Civiale (2009)
10.1208/s12249-009-9268-4
Nanoemulsion as a Potential Ophthalmic Delivery System for Dorzolamide Hydrochloride
H. Ammar (2009)
10.1023/A:1016015803611
Polyester Nanocapsules as New Topical Ocular Delivery Systems for Cyclosporin A
P. Calvo (2004)
Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome.
P. Argüeso (2002)
10.1023/A:1018977130559
Design of New Formulations for Topical Ocular Administration: Polymeric Nanocapsules Containing Metipranolol
C. Losa (2004)
10.1016/J.IJPHARM.2003.11.032
Micellar solutions of triblock copolymer surfactants with pilocarpine.
I. Pepić (2004)
10.1016/j.carbpol.2013.10.079
In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma.
Shefali Katiyar (2014)
10.1111/jphp.12134
Size‐dependent internalisation of folate‐decorated nanoparticles via the pathways of clathrin and caveolae‐mediated endocytosis in ARPE‐19 cells
Wai‐Leung Langston Suen (2014)
10.3109/10611860903450023
Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation
Sheetu Wadhwa (2010)
10.1093/hmg/ddq146
Overexpression of optineurin E50K disrupts Rab8 interaction and leads to a progressive retinal degeneration in mice
Zai-Long Chi (2010)
10.1016/j.jconrel.2009.02.020
Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye.
K. Hironaka (2009)
10.1016/S0142-9612(02)00080-7
Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application.
R. Pignatello (2002)
10.1002/jbm.a.34467
Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops.
Mohd Abul Kalam (2013)
10.1021/BM7008203
Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells.
N. Stasko (2007)
10.4103/0250-474X.84575
Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics
R. K. Khar (2010)
10.2147/OPTH.S45444
Diagnosis of dry eye disease and emerging technologies
Maya Salomon-Ben Zeev (2014)
10.1016/S0378-5173(99)00348-8
Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits.
A. S. Monem (2000)
Diffusion of high molecular weight compounds through sclera.
J. Ambati (2000)
10.1016/0169-409X(95)00010-5
Ocular absorption following topical delivery
K. Järvinen (1995)
10.4103/0975-1483.71623
Preparation and Evaluation of Nano-vesicles of Brimonidine Tartrate as an Ocular Drug Delivery System
P. Prabhu (2010)
10.1016/S0140-6736(04)16257-0
Primary open-angle glaucoma
R. Weinreb (2004)
10.1016/j.jconrel.2011.07.002
"Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era.
Ae Jung Huh (2011)
10.3109/02652048.2010.523794
Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery
M. Ahuja (2011)
10.1208/s12249-011-9675-1
Brimonidine Tartrate–Eudragit Long-Acting Nanoparticles: Formulation, Optimization, In Vitro and In Vivo Evaluation
Prakash Bhagav (2011)
10.1016/j.exer.2008.04.002
Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea.
I. Yenice (2008)
10.1248/BPB.32.1266
Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid.
M. Yamaguchi (2009)
10.1039/C3RA47370H
Polymeric micelles as drug delivery vehicles
Z. Ahmad (2014)
10.1089/jop.2013.0157
Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility.
A. D. Vadlapudi (2014)
10.1002/bdd.778
The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits
M. Shafaa (2011)
10.1159/000267160
A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits.
S. Muchtar (1992)
10.1038/gt.2008.16
Bioadhesive hyaluronan–chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue
M. Fuente (2008)
10.1016/J.IJPHARM.2007.03.011
Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
M. Kassem (2007)
Polymeric Micelles in Ocular Drug Delivery: Rationale, Strategies and Challenges
I. Pepić (2012)
10.3109/10717544.2014.943336
Liposomes in topical ophthalmic drug delivery: an update
R. Agarwal (2016)
10.1016/S0378-5173(00)00443-9
Increased partitioning of pilocarpine to the oily phase of submicron emulsion does not result in improved ocular bioavailability.
M. Sznitowska (2000)



This paper is referenced by
10.2147/IJN.S244785
Silver Nanoparticle-Induced Apoptosis in ARPE-19 Cells Is Inhibited by Toxoplasma gondii Pre-Infection Through Suppression of NOX4-Dependent ROS Generation
J. Quan (2020)
Therapeutics Applications of Nanosuspension in Topical/ Mucosal Drug Delivery
(2018)
10.3390/biomedicines8110466
Polymeric Inserts Containing Eudragit® L100 Nanoparticle for Improved Ocular Delivery of Azithromycin
Shiva Taghe (2020)
10.1208/s12249-020-01699-9
Formulation of Chitosan Polymeric Vesicles of Ciprofloxacin for Ocular Delivery: Box-Behnken Optimization, In Vitro Characterization, HET-CAM Irritation, and Antimicrobial Assessment
Ameeduzzafar (2020)
10.1080/17435390.2016.1181808
Poly(ortho ester) nanoparticles targeted for chronic intraocular diseases: ocular safety and localization after intravitreal injection
H. Li (2016)
10.1039/c9nr00376b
Synergistically dual-functional nano eye-drops for simultaneous anti-inflammatory and anti-oxidative treatment of dry eye disease.
Yu-Jia Li (2019)
10.22270/jddt.v10i1-s.3853
Formulation and Characterization of Moxifloxacin Nanoparticles with Ion Exchange Resin
Jigar Vyas (2020)
10.2147/IJN.S109986
Visual tracing of diffusion and biodistribution for amphiphilic cationic nanoparticles using photoacoustic imaging after ex vivo intravitreal injections
Xu Xu (2016)
10.1007/164_2016_84
Ocular Drug Delivery.
B. Yavuz (2017)
10.1016/j.tox.2020.152540
Involvement of endoplasmic reticulum stress response and IRE1-mediated ASK1/JNK/Mcl-1 pathways in silver nanoparticle-induced apoptosis of human retinal pigment epithelial cells.
Juan-Hua Quan (2020)
Utjecaj procesnih parametara visokotlačne homogenizacije i mikrofluidizacije na svojstva i stabilnost nanoemulzija
Anđela Popović (2017)
10.22038/ijbms.2020.43447.10205
Preparation and in vivo evaluation of nanoliposomes containing vancomycin after intravitreal injection in albino rabbits
M. Abrishami (2020)
10.1016/j.colsurfb.2015.11.059
Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca.
F. Ying-fang (2016)
10.1016/j.colsurfb.2016.08.048
Improving the topical ocular pharmacokinetics of an immunosuppressant agent with mucoadhesive nanoemulsions: Formulation development, in-vitro and in-vivo studies.
S. Akhter (2016)
10.1016/j.nano.2016.08.007
Safety of nanosuspensions in drug delivery.
L. Wang (2017)
10.1016/j.ijbiomac.2020.07.306
Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect.
M. Donia (2020)
10.1002/mabi.201700261
Hyaluronic Acid-Based Micelles as Ocular Platform to Modulate the Loading, Release, and Corneal Permeation of Corticosteroids.
F. Bongiovì (2017)
10.1007/978-3-030-31261-9_8
Nanoparticles for Cornea Therapeutic Applications: Treating Herpes Simplex Viral Infections
Fiona Simpson (2019)
10.2217/nnm-2017-0305
Utility of nanomedicine targeting scar-forming myofibroblasts to attenuate corneal scarring and haze.
Aseel Mahmood Ibrahim Al-Mashahedah (2019)
10.1007/s12553-019-00381-w
Application of nanoparticles in ocular drug delivery systems
Naida Omerović (2020)
10.1007/978-3-319-95807-1_11
Nanomedicine-Based Delivery to the Posterior Segment of the Eye: Brighter Tomorrow
A. J. Abd (2018)
10.1590/S2175-97902019000117105
Preparation and characterization of novel, mucoadhesive ofloxacin nanoparticles for ocular drug delivery
Shiva Taghe (2019)
10.1016/j.ijpharm.2020.119577
The prominence of the dosage form design to treat ocular diseases.
Patrícia Mazureki Campos (2020)
Razvoj oftalmičkih nanoemulzija sa stearilaminom
Ana Bračko (2019)
Identification et vectorisation de combinaisons de traitements pour la thérapie des tumeurs pulmonaires résistantes aux inhibiteurs de tyrosine kinase de l'EGFR
V. Jeannot (2015)
10.3390/ijms19092830
Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application
Cheng-Han Tsai (2018)
10.1016/B978-0-12-409547-2.12292-9
Nanotechnology in drug discovery and development
L. Gutiérrez (2017)
10.1016/j.jcis.2019.04.032
Visible light-triggered cargo release from donor acceptor Stenhouse adduct (DASA)-doped lyotropic liquid crystalline nanoparticles.
Shiyang Jia (2019)
10.1016/j.jddst.2020.101736
Nanoparticles laden In situ gel for sustained drug release after topical ocular administration
U. UpadhyayShivam (2020)
Evaluación del potencial antimicrobiano de extractos de plantas frente a microorganismos asociados a conjuntivitis bacterianas
V. García (2018)
10.1016/j.drudis.2018.01.016
Pharmaceutical nanocrystals: production by wet milling and applications.
M. Malamatari (2018)
10.1016/j.cclet.2017.07.022
Pediatric ocular nanomedicines: Challenges and opportunities.
N. Sheybani (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar